Patents Assigned to Amgen Boulder Inc.
  • Patent number: 6132990
    Abstract: A synthetic DNA sequence and its genetic equivalents are disclosed which sequences are capable, when used in a recombinant DNA method, of directing production of a serine protease inibitor protein. Recombinant DNA methods for the production of serine protease inhibitor proteins are also disclosed. These methods incorporate either the synthetic DNA sequence of the present invention or natural DNA sequences isolated from human cDNA or genomic libraries.In addition, a single polypeptide chain protein is disclosed which is capable of inhibiting chymotrypsin and elastase but not trypsin. In one embodiment, this protein is a shortened from (single domain) of the protein produced by the method described herein.
    Type: Grant
    Filed: June 7, 1991
    Date of Patent: October 17, 2000
    Assignee: Amgen Boulder Inc.
    Inventors: Pradip K. Bandyopadhyay, Stephen P. Eisenberg, Gary L. Stetler, Robert C. Thompson
  • Patent number: 5843791
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 1, 1998
    Assignee: Amgen Boulder Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • Patent number: 5747639
    Abstract: The present invention relates to a process for purifying polyethylene glycols (PEGs) which utilizes hydrophobic interaction chromatography (HIC) to separate the PEGs based on their size and on their end-group functionality. The purified PEGs can be used to modify biologically active molecules and improve overall production of such molecules.
    Type: Grant
    Filed: March 6, 1996
    Date of Patent: May 5, 1998
    Assignee: Amgen Boulder Inc.
    Inventor: James Ervin Seely